Site updated at Wednesday, 22 June 2016

Living with Dementia

Team Unravels Central Mystery of Alzheimer’s

  • - Dementia News
  • Apr 10, 2013
  • Comments
  • Viewed: 354
Tags: | alzheimers disease | amyloid plaques | beta-amyloid | dementia |

Scientists at The Scripps Research Institute (TSRI) have shed light on one of the major toxic mechanisms of Alzheimer’s disease. The discoveries could lead to a much better understanding of the Alzheimer’s process and how to prevent it.

The findings, reported in the April 10, 2013 issue of the journal Neuron, show that brain damage in Alzheimer’s disease is linked to the overactivation of an enzyme called AMPK. When the scientists blocked this enzyme in mouse models of the disease, neurons were protected from loss of synapses- neuron-to-neuron connection points- typical of the early phase of Alzheimer’s disease.

“These findings open up many new avenues of investigation, including the possibility of developing therapies that target the upstream mechanisms leading to AMPK overactivation in the brain,” said TSRI Professor Franck Polleux, who led the new study.

Alzheimer’s disease, a fatal neurodegenerative disorder afflicting more than 25 million people worldwide, currently has no cure or even disease-delaying therapy.

In addition to having implications for Alzheimer’s drug discovery, Polleux noted the findings suggest the need for further safety studies on an existing drug, metformin. Metformin, a popular treatment for Type 2 Diabetes, causes AMPK activation.

Tantalizing Clues to Alzheimer’s

Researchers have known for years that people in the earliest stages of Alzheimer’s disease begin to lose synapses in certain memory-related brain areas. Small aggregates of the protein amyloid beta can cause this loss of synapses, but how they do so has been a mystery.

Until recently, Polleux’s laboratory has been focused not on Alzheimer’s research but on the normal development and growth of neurons. In 2011, he and his colleagues reported that AMPK overactivation by metformin, among other compounds, in animal models impaired the ability of neurons to grow output stalks, or axons.

These disruptions cause nerve cells in the brain to stop working, lose connections with other nerve cells, and finally die. The destruction and death of nerve cells causes the memory failure, personality changes, problems in carrying out daily activities, and other features of the disease.

The brains of people with AD have an abundance of two abnormal structures - amyloid plaques and neurofibrillary tangles - that are made of
misfolded proteins.

This is especially true in certain regions of the brain that are important in memory.

The third main feature of AD is the loss of connections between cells. This leads to diminished cell function and cell death

Around the same time, separate research groups found clues that AMPK might also have a role in Alzheimer’s disease. One group reported that AMPK can be activated in neurons by amyloid beta, which in turn can cause a modification of the protein tau in a process known as phosphorylation. Tangles of tau with multiple phosphorylations (“hyperphosphorylated” tau) are known to accumulate in neurons in affected brain areas in Alzheimer’s. These results, published two years ago, reported abnormally high levels of activated AMPK in these tangle-ridden neurons.

Polleux decided to investigate further, to determine whether the reported interactions of AMPK with amyloid beta and tau can in fact cause the damage seen in the brains of Alzheimer’s patients. “Very little was known about the function of this AMPK pathway in neurons, and we happened to have all the tools needed to study it,” he said.

The Mystery of Alzheimer’s
When searching for Alzheimer’s some doctors will carry out a physical exam, take blood and urine samples, order a brain scan, or carry out memory or psychological tests to see how well the brain is working. There is no specific test for identifying Alzheimer’s. You should take the person you suspect has Alzheimer’s to the doctor when memory seems to be affecting their entire life. You may notice they struggle doing daily things. But remember people’s memories do deplete as they get older so if their memory does not seem to be affecting their daily lives they should be just fine. When the doctors carry out physical exams they will be asking about diet, nutrition, and use of alcohol. They will want medical history. The test may also include taking blood pressure and taking a temperature.

In Search of Answers

Georges Mairet-Coello, a postdoctoral research associate in the Polleux lab, performed most of the experiments for the new study. He began by confirming that amyloid beta, in the small-aggregate (“oligomer”) form that is toxic to synapses, does indeed strongly activate AMPK; amyloid beta oligomers stimulate certain neuronal receptors, which in turn causes an influx of calcium ions into the neurons. He found that this calcium influx triggers the activation of an enzyme called CAMKK2, which appears to be the main activator of AMPK in neurons.

The team then showed that this AMPK overactivation in neurons is the essential reason for amyloid beta’s synapse-harming effect. Normally, the addition of amyloid beta oligomers to a culture of neurons causes the swift disappearance of many of the neurons’ dendritic spines- the rootlike, synapse-bearing input stalks that receive signals from other neurons. With a variety of tests, the scientists showed that amyloid beta oligomers can’t cause this dendritic spine loss unless AMPK overactivation occurs- and indeed AMPK overactivation on its own can cause the spine loss.

Stages of Alzheimer’s

Stage 1: They act normal. No signs of any forms of dementia.

Stage 2: Very mild decline in memory. The person may have some memory lapses. They may forget familiar words or locations as well as some everyday objects. But still no signs that could be diagnosed.

Stage 3: Mild decline and can sometimes be detected. Friends or family may notice changes. Doctors may notice memory or concentration problems like coming up with words, trouble remembering names, having problems doing tasks at work, losing or misplacing valuable objects, or increased problems with planning or organizing.

Stage 4: Mild moderate severe decline is the mid-stage of Alzheimer’s. At this stage thorough medical interviews should take place and be diagnosed as some form of dementia. Some symptoms are forgetfulness of recent events, impaired ability to do simple math questions, difficulty planning, forgetfulness of one’s history and personal information, and becoming moody or withdrawn from people.

Stage 5: Moderate severe decline which is called the moderate mid-stage of Alzheimer’s. Gaps in memory or thinking are obvious and the person may need help doing daily tasks. Some signs are they won’t be able to remember personal information, confusion with time and dates, having issues with numbers and math, need help choosing proper clothing for weather or occasions, yet don’t need help with eating or bathing, and they remember some significant details about them and their family.

Stage 6: Severe decline and it is still mid-stage of Alzheimer’s. Memory will continue to worsen and at this stage they might lose awareness of recent experiences as well as their surroundings, difficulty remembering their own name, trouble remembering unfamiliar and familiar people, needs help dressing properly, experience major changes in sleep patterns, have trouble controlling when to get rid of waste from the body, experience major personality changes, and they may wander and get lost.

Stage 7: Very severe decline in Alzheimer’s, this is the late stage in Alzheimer’s. In the final stage of Alzheimer’s people may lose the ability to carry on a conversation and participate in daily life. They may still be able to say some words or phrases. At this stage people will need help with everything from eating, to getting rid of waste, to cleaning themselves, or sitting up on their own. They may lose the ability to smile and their reflexes become abnormal and muscles become rigid.

For a key experiment the team used J20 mice, which are genetically engineered to overproduce mutant amyloid beta, and eventually develop an Alzheimer’s-like condition. “When J20 mice are only three months old, they already show a strong decrease in dendritic spine density, in a set of memory-related neurons that are also affected early in human Alzheimer’s,” Mairet-Coello said. “But when we blocked the activity of CAMKK2 or AMPK in these neurons, we completely prevented the spine loss.”

Page 1

1 2 Next »

Post a comment [ + Comment here + ]

There are no comments for this entry yet. [ + Comment here + ]

Your details

* Required field

Please enter the word you see in the image below:

Comments are moderated by our editors, so there may be a delay between submission and publication of your comment. Offensive or abusive comments will not be published.

Going Home (A short film on Dementia)

cerebrovascular disease1 - symptoms of dementia3 - korsakoff amnesic syndrome1 - decline in memory1 - cognitive ability1 - symptoms of vascular dementia1 - alzheimer's brain1 - apoplectic dementia1 - reconceptualization1 - hiv dementia1 - amyloid-beta4 - depressive pseudodementia1 - cvd1 - hiv infection1 - vessel disease1 - alzheimer’s disease8 - forms of dementia2 - risk for dementia1 - memantine1 - brain changes1 - protein amyloid beta1 - cinnamon1 - hormone replacement therapy1 - national alzheimer's project act1 - mmse1 - social support1 - chuanhai cao1 - amentia2 - dbs1 - memory impairment2 -